Neurobiology of Depression and Antidepressant Mechanisms

The hypothesis emerged in the 1960s from two accidental clinical observations. First, reserpine — a drug used at the time to treat hypertension — depletes vesicular stores of serotonin, norepinephrine, and dopamine and was found to cause depression in a significant proportion of patients who received it. Second, the first antidepressants discovered (the monoamine oxidase inhibitors and the tricyclic antidepressants) were both found to increase synaptic availability of monoamines, either by blocking their enzymatic breakdown or by blocking their reuptake transporters.

Together these findings pointed toward the same conclusion: low monoamine activity at synapses is associated with depression, and raising monoamine activity produces antidepressant effects. This reuptake blockade model remains the mechanistic basis for most antidepressants in clinical use today.

Serotonin is the primary target of the most widely prescribed antidepressants. Serotonergic neurons projecting from the dorsal raphe nucleus to the limbic system and prefrontal cortex regulate mood, anxiety, sleep, and appetite. Deficiency in this projection is linked to the core emotional symptoms of depression — low mood, anhedonia, and anxiety.

Norepinephrine projecting from the locus coeruleus modulates attention, arousal, and the stress response. Norepinephrine deficiency contributes to the fatigue, poor concentration, and psychomotor retardation seen in depression. The dual reuptake inhibitors — the serotonin-norepinephrine reuptake inhibitors and the tricyclic antidepressants — target both transporters and are particularly effective for depression with prominent fatigue and pain.

Dopamine, projecting through the mesolimbic and mesocortical pathways, governs motivation and reward. Dopamine deficiency underlies the anhedonia that is a hallmark of severe depression. Bupropion, which selectively blocks the dopamine and norepinephrine transporters without affecting serotonin, demonstrates that dopaminergic enhancement alone can be antidepressant.

The monoamine hypothesis is useful as a pharmacological target model, but it is incomplete as a disease explanation. Several observations challenge it as a full account of depression. Reuptake blockade occurs within hours of the first dose, yet antidepressant benefit requires two to four weeks — a mismatch that the hypothesis alone cannot explain. Additionally, not all patients with depression respond to monoaminergic drugs, and some treatments with no monoaminergic mechanism (such as electroconvulsive therapy and ketamine) are highly effective. The hypothesis should be understood as identifying where most antidepressants act, not why depression occurs.

Virtually all antidepressants are eliminated primarily by hepatic metabolism through the cytochrome P450 enzyme system. The most clinically relevant isoforms are cytochrome P450 2D6, cytochrome P450 3A4, cytochrome P450 2C19, and cytochrome P450 1A2. Drug interactions arise in two directions: antidepressants as substrates of these enzymes (their metabolism is affected by inhibitors and inducers), and antidepressants as inhibitors of these enzymes (they raise plasma levels of other drugs metabolized by the same isoform).

Among the selective serotonin reuptake inhibitors, fluoxetine and paroxetine are potent inhibitors of cytochrome P450 2D6 — clinically significant because cytochrome P450 2D6 metabolizes many commonly prescribed drugs including antipsychotics, opioids, and beta-blockers. Fluvoxamine is a potent cytochrome P450 1A2 inhibitor. Escitalopram and sertraline have the cleanest inhibition profiles among the selective serotonin reuptake inhibitors, making them preferred when polypharmacy is a concern. Cytochrome P450 2D6 also shows clinically significant genetic polymorphism — roughly 7 to 10 percent of individuals of European ancestry are poor metabolizers who achieve substantially higher plasma levels of cytochrome P450 2D6-metabolized drugs at standard doses.

Several antidepressants produce pharmacologically active metabolites that carry significant clinical consequences. Fluoxetine is converted to norfluoxetine, which has a half-life of one to two weeks and inhibits the serotonin reuptake transporter with similar potency to the parent drug. This active metabolite makes fluoxetine functionally self-tapering — abrupt discontinuation causes minimal discontinuation syndrome — and it requires a five-week washout before initiating a monoamine oxidase inhibitor (versus two weeks for other selective serotonin reuptake inhibitors).

Venlafaxine is metabolized to desvenlafaxine (O-desmethylvenlafaxine), which has been developed and approved as a separate antidepressant. Amitriptyline and imipramine are demethylated to nortriptyline and desipramine respectively — each of which is an approved antidepressant with a somewhat different pharmacological profile than the parent compound.

Half-life is the most clinically relevant pharmacokinetic parameter for antidepressants in practice. It governs the time to steady state after dose changes (approximately five half-lives), the risk of discontinuation syndrome upon abrupt cessation, and the washout period required before starting a monoamine oxidase inhibitor.

Antidepressants with short half-lives — particularly paroxetine and venlafaxine immediate-release — carry the highest risk of discontinuation syndrome and require gradual tapering when stopping. Fluoxetine, with its long-acting active metabolite norfluoxetine, carries the lowest discontinuation syndrome risk among the selective serotonin reuptake inhibitors. The discontinuation syndrome itself and monoamine oxidase inhibitor washout periods are covered in detail in Module 7.